Your browser doesn't support javascript.
loading
Natural history and clinical outcomes of patients with hypertrophic cardiomyopathy from thin filament mutations.
Saul, Tatiana; Bui, Quan M; Argiro, Alessia; Keyt, Lucas; Olivotto, Iacopo; Adler, Eric.
Affiliation
  • Saul T; Division of Cardiovascular Medicine, Department of Medicine, University of California, San Diego, San Diego, California, USA.
  • Bui QM; Division of Cardiovascular Medicine, Department of Medicine, University of California, San Diego, San Diego, California, USA.
  • Argiro A; Cardiomyopathy Unit, Careggi University Hospital, Florence, Italy.
  • Keyt L; Division of Cardiovascular Medicine, Department of Medicine, University of California, San Diego, San Diego, California, USA.
  • Olivotto I; Cardiomyopathy Unit, Careggi University Hospital, Florence, Italy.
  • Adler E; Division of Cardiovascular Medicine, Department of Medicine, University of California, San Diego, San Diego, California, USA.
ESC Heart Fail ; 2024 May 21.
Article in En | MEDLINE | ID: mdl-38773858
ABSTRACT
Hypertrophic cardiomyopathy (HCM) due to thick filament variants is more common; however, HCM due to thin filament variants (HCM-Thin) may be associated with a more malignant phenotype with an increased risk of sudden cardiac death. The aim of this study was to review all the published cases of HCM-Thin to better understand the natural history and clinical outcomes of this disease. A literature review of HCM-Thin identified 21 studies with a total of 177 patients that were suitable for analysis. There were three outcomes of interest, which included a heart failure composite, a ventricular arrhythmia composite and a heart failure and arrhythmia composite outcome. Kaplan-Meier (KM) survival analyses for freedom from each of the abovementioned composite outcomes were completed for the entire cohort and stratified by age of onset and sarcomeric variant. The heart failure composite occurred in 24 (13.6%) patients, the ventricular arrhythmia composite occurred in 30 patients (16.9%) and the combined heart failure and arrhythmia composite occurred in 50 patients (28.2%). In regard to left ventricular ejection fraction (LVEF), the majority of patients were preserved (LVEF > 50%) compared with mildly reduced (LVEF 41%-50%) and reduced (LVEF ≤ 40%) (respectively 26.6% vs. 0.6% vs. 3.4%). The median maximal left ventricular wall thickness (LVWT) was 19.0 mm [interquartile range (IQR) 5.3]. Only 10.7% of the cohort had evidence of left ventricular outflow tract (LVOT) obstruction. Those with paediatric-onset HCM had earlier onset and were at higher risk for each endpoint than their adult counterparts. When stratified by genetic variant, patients with TNNI3 and TPM1 were at a higher risk of the heart failure composite endpoint and the combined heart failure and arrhythmia composite endpoint in comparison with those with the other genetic variants. HCM-Thin is associated with significant morbidity and mortality, with a high arrhythmia burden despite low rates of cardiac obstruction and mild hypertrophy. The paediatric onset of disease and certain sarcomeric variants appear to be associated with a worse prognosis than their adult-onset and other sarcomeric variant counterparts. HCM-Thin seems to have a distinct phenotype, which may require a different management approach.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: ESC Heart Fail Year: 2024 Document type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: ESC Heart Fail Year: 2024 Document type: Article Affiliation country: United States